Brief: Celyad To Accelerate CYAD-01 Program In R/R AML And MDS

Celyad Oncology SA

07/01/2019 06:12

Jan 7 (Reuters) - CELYAD SA  CYAD.BR :
    * CELYAD OUTLINES KEY 2019 PRIORITIES INCLUDING THE
ACCELERATION
OF THE CYAD-01 PROGRAM IN R/R AML AND MDS
    * LEAD CANDIDATE CYAD-01 CONTINUES TO DEMONSTRATE
ENCOURAGING
CLINICAL ACTIVITY IN THINK PHASE 1 TRIAL
    * INITIATION OF A PHASE 2 CLINICAL TRIAL DURING SECOND HALF
2019
    * KEY FOCUS TO ACCELERATE DEVELOPMENT OF CYAD-01 FOR
TREATMENT OF
PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE MYELOID
LEUKEMIA (AML) OR MDS
    * OVER NEXT 12 MONTHS: INTENDS TO REPORT ADDITIONAL DATA
FROM
PHASE 1 DOSE-ESCALATION THINK TRIAL FOR CYAD-01 IN R/R AML OR
MDS PATIENTS
    * IN 2019 AIMS TO  PRESENT IN VIVO PRECLINICAL DATA FOR
NON-GENE
EDITED ALLOGENEIC SHRNA PLATFORM

Source text for Eikon:  ID:nGNX3ypv4s 
Further company coverage:  CYAD.BR 

 (Gdynia Newsroom:)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))